JP2020015733A5 - - Google Patents

Download PDF

Info

Publication number
JP2020015733A5
JP2020015733A5 JP2019149672A JP2019149672A JP2020015733A5 JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5 JP 2019149672 A JP2019149672 A JP 2019149672A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
polypeptide
subject
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019149672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020015733A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2019149672A priority Critical patent/JP2020015733A/ja
Priority claimed from JP2019149672A external-priority patent/JP2020015733A/ja
Publication of JP2020015733A publication Critical patent/JP2020015733A/ja
Publication of JP2020015733A5 publication Critical patent/JP2020015733A5/ja
Pending legal-status Critical Current

Links

JP2019149672A 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド Pending JP2020015733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019149672A JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015553175A Division JP2016506914A (ja) 2013-01-16 2013-01-16 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Publications (2)

Publication Number Publication Date
JP2020015733A JP2020015733A (ja) 2020-01-30
JP2020015733A5 true JP2020015733A5 (https=) 2020-09-10

Family

ID=69580027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019149672A Pending JP2020015733A (ja) 2019-08-19 2019-08-19 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド

Country Status (1)

Country Link
JP (1) JP2020015733A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
AU2024240722A1 (en) * 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69619526T2 (de) * 1995-06-12 2002-10-31 Yeda Research And Development Co., Ltd. Fgf9 als spezifischer ligand für fgfr3
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2558758C (en) * 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Similar Documents

Publication Publication Date Title
US20240131118A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
DE69433820T2 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
KR101673654B1 (ko) 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제
US20240226236A9 (en) Nerve growth factor fusion protein, preparation method and use thereof
DK2633865T3 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS
JP2010518079A5 (https=)
JP2016537340A5 (https=)
BRPI0622256A2 (pt) formulações estáveis adequadas para administração subcutánea compreendendo moléculas de ctla4ig
JP2017057216A (ja) 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
CA3128113A1 (en) Pharmaceutical taci-fc fusion protein formulation
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
JP2016506914A5 (https=)
JP2016506912A5 (https=)
AU2024204870A1 (en) Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin
JP2020015733A5 (https=)
EP3169348B1 (en) Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases
JP6480154B2 (ja) エタネルセプトの凍結乾燥製剤
AU2019364063B2 (en) Pharmaceutical composition for treating aplastic anemia
EP1596879B1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Weaver Efficacy and safety of the anti-TNF biologic agents
KR20250048156A (ko) 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
JP2022515468A (ja) Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用
HK40059370A (en) Pharmaceutical composition for treating aplastic anemia
HK40012327A (en) Peptides for treating sjogren's syndrome